Fortis Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Fortis Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$499K	Hold	3,906	–	–	0.25%	66
2025 Q4	$476K	Sell	3,906 -770	-16%	-$88.3K	0.26%	65
2025 Q3	$469K	Sell	4,676 -500	-10%	-$45K	0.26%	66
2025 Q2	$429K	Sell	5,176 -774	-13%	-$61.7K	0.27%	68
2025 Q1	$483K	Hold	5,950	–	–	0.31%	60
2024 Q4	$536K	Buy	5,950 +650	+12%	+$63K	0.35%	52
2024 Q3	$524K	Hold	5,300	–	–	0.34%	54
2024 Q2	$491K	Buy	5,300 +1,150	+28%	+$103K	0.35%	45
2024 Q1	$394K	Hold	4,150	–	–	0.26%	61
2023 Q4	$371K	Hold	4,150	–	–	0.26%	61
2023 Q3	$303K	Hold	4,150	–	–	0.23%	71
2023 Q2	$345K	Hold	4,150	–	–	0.25%	63
2023 Q1	$316K	Hold	4,150	–	–	0.21%	68
2022 Q4	$344K	Hold	4,150	–	–	0.26%	62
2022 Q3	$329K	Buy	4,150 +500	+14%	+$42.2K	0.23%	65
2022 Q2	$271K	Buy	3,650 +650	+22%	+$48.8K	0.18%	77
2022 Q1	$270K	Buy	+3,000	New	+$277K	0.15%	84

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fortis Advisors's XBI Position: Q1 2026 in Review

Fortis Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 3,906 shares worth $499K. The position accounts for 0.25% of the portfolio, ranked #66.

Fortis Advisors first reported a position in XBI in Q1 2022 and has held it in 17 quarters since. The position peaked at $536K in Q4 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Fortis Advisors held 3,906 shares of State Street SPDR S&P Biotech ETF worth $499K as of Q1 2026.
Fortis Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.25% of Fortis Advisors's portfolio in Q1 2026, its #66 holding.
Fortis Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 17 quarters since.
Fortis Advisors's State Street SPDR S&P Biotech ETF position peaked at $536K in Q4 2024.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Fortis Advisors's 13F filing for Q1 2026, filed 14 May 2026.